Eureka Therapeutics
CA - Emeryville
Biotechnology6 H-1B visas (FY2023)Focus: Antibodies
Eureka Therapeutics is a life sciences company focused on Antibodies.
OncologyGastroenterology
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
Brain Blossom - Gamified Differential Outcome Training
Mild Cognitive ImpairmentClinical Trials (1)
NCT06399978The Feasibility and Effect of Digital Cognitive Training in Mild Cognitive Impairment
N/AClinician and Non-clinician staff training
LGBT HealthN/A
Clinical Trials (1)
NCT06402266Simultaneous tDCS and Computerised Gamified Short-term Memory Task Feasibility
N/ASorafenib combined with ET140202-T cell
Hepatocellular CarcinomaClinical Trials (1)
NCT03965546ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer
Phase 1ET140203 autologous T cell product
Hepatocellular CarcinomaClinical Trials (1)
NCT04502082Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)
Phase 1ET190L1 ARTEMIS™ T cells
Lymphomas Non-Hodgkin's B-CellClinical Trials (1)
NCT03379493Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma
Phase 1ET190L1-ARTEMIS™ T cells -iv low dose
CD19+ Lymphoma, B-CellClinical Trials (1)
NCT03895944ET190L1-ARTEMIS™ T Cells in Relapsed, Refractory B Cell Leukemia and Lymphoma
Phase 1Low dose ET019002- T Cells
B-Cell MalignanciesClinical Trials (1)
NCT03642496Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies
Phase 1ET1402L1-ARTEMIS™ T cells -IV
Hepatocellular CarcinomaClinical Trials (1)
NCT03888859ET1402L1-ARTEMIS™2 T Cells in Alpha Fetoprotein (AFP) Expressing Hepatocellular Carcinoma
Phase 1Conditioning chemotherapy followed by AbTCR
Diffuse Large B Cell Lymphoma (DLBCL)Clinical Trials (1)
NCT07168291Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma
Phase 1ET140202 autologous T cell product
Hepatocellular CarcinomaClinical Trials (1)
NCT03998033Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma
Phase 1ET019003-T Cells
LeukemiaClinical Trials (1)
NCT04014894ET019003-T Cells in Relapsed/Refractory CD19+ B-Cell Leukemia and Lymphoma
Phase 1autologous ET1402L1-CART cells
Hepatocellular CarcinomaClinical Trials (1)
NCT03349255Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma
Phase 1ET190L1 ARTEMIS™ T cells
Lymphoma, B-CellClinical Trials (1)
NCT03415399Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma
Phase 1Phase 1/2
Clinical Trials (1)
NCT06343311T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Phase 1/2ET140203 T Cells
HepatoblastomaClinical Trials (1)
NCT04634357ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
Phase 1/2ECT204 T cells
Hepatocellular CarcinomaClinical Trials (1)
NCT04864054T-Cell Therapy (ECT204) in Adults With Advanced HCC
Phase 1/2Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 16 clinical trials
H-1B (2023): 6 approvals
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
6
Approved
1
Denied
86%
Rate
Source: USCIS H-1B Employer Data Hub